The new label for Alecensa makes it the first targeted treatment available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.
With the FDA nod, Alecensa becomes the second molecularly targeted therapy to move into the adjuvant setting for non-small cell lung cancer.
The start of the opioid epidemic is ironically linked to a drug that was supposed to help people suffering from moderate to ...
The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.
This issue of the Mass Torts Update addresses the United Judicial Panel on Multidistrict Litigation ordering the ...
Columnist Teri Sforza writes that researchers are searching for medication to help and several look promising.
A new additional drug in the fight against the opioid overdose crisis has slowly been making its way across the country and ...
The House Committee on Veterans' Affairs approved a pair of cannabis and psychedelics bills on Tuesday . Committee members ...
Kids Can't Wait Any Longer For Social Media Safety When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, ...
In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA ...
Opsynvi, a Single-Tablet Combo Therapy for PAH, Gets FDA Approval Praluent (alirocumab) Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor As an adjunct to diet and other low density ...
Some argue a need for more potent — and pricier — overdose reversal drugs; others frame that effort as drugmakers peddling ...